Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Esperion (NASDAQ: ESPR) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference scheduled for Wednesday, January 15, 2025, at 3:45 p.m. PT. The presentation will be accessible via webcast through Esperion's investor and media section, with replay available for approximately 90 days.

Esperion is a commercial stage biopharmaceutical company that has developed the only FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk. These medications are backed by the CLEAR Cardiovascular Outcomes Trial, which involved nearly 14,000 patients.

The company is advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi), leveraging new structural and functional insights for developing highly potent and specific inhibitors with allosteric mechanisms. Esperion aims to expand globally through commercial execution, international partnerships, and pre-clinical pipeline advancement.

ANN ARBOR, Mich., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET).

The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.

Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.

Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and esperionscience.com and follow Esperion on LinkedIn and X.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

FAQ

When is Esperion (ESPR) presenting at the 2025 J.P. Morgan Healthcare Conference?

Esperion is scheduled to present on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET).

How long will Esperion's (ESPR) J.P. Morgan Conference webcast be available for replay?

The webcast replay will be archived on Esperion's website for approximately 90 days after the presentation.

What are the key therapeutic areas Esperion (ESPR) is focusing on in 2025?

Esperion is focusing on non-statin medicines for elevated LDL-C and cardiovascular disease risk, along with developing next-generation ATP citrate lyase inhibitors (ACLYi).

How many patients were involved in Esperion's CLEAR Cardiovascular Outcomes Trial?

The CLEAR Cardiovascular Outcomes Trial included nearly 14,000 patients.

What distinguishes Esperion's (ESPR) FDA-approved medications in the market?

They are the only FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk.